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Oral anticoagulation for cerebral
ischemia of arterial origin
High initial bleeding risk
M. Torn, MD; A. Algra, MD; and F.R. Rosendaal, MD
Article abstract—Background: The use of oral anticoagulant therapy for the prevention of arterial thromboembolism in
patients who have had ischemic stroke is controversial. Coumarins may increase the bleeding risk in patients with
cerebral ischemia of arterial origin. Objectives: 1) To calculate incidence rates of bleeding and thromboembolic events in
patients with noncardiac cerebral ischemia who were treated routinely in an anticoagulation clinic. 2) To assess which
factors contribute to the occurrence of events. 3) To determine the optimal intensity of oral anticoagulant therapy in these
patients. Methode: The authors studied all patients treated for noncardiac cerebral ischemia at the Leiden anticoagulation
clinic between 1993 and 1998. Outcome events were major hemorrhage, major arterial thromboembolism, and death.
Results: The authors observed 356 patients for 644 patient-years. The incidence of major hemorrhage was 3.9 per 100
patient-years (95% CI, 2.5 to 5.7) and that of thromboembolism was 3.0 per 100 patient-years (95% CI, 1.8 to 4.6). The
incidence of hemorrhage varied with the duration of treatment (relative risk [RR] of the first versus the second half-year,
3.8; 95% CI, 1.9 to 7.6), age (RR for age >65 years, 3.7; 95% CI, 1.1 to 12.3), and the intensity of oral anticoagulation (RR,
1.8 for each 0.5 international normalized ratio [INR] unit increase; 95% CI, 1.5 to 2.3). The optimal intensity of oral
anticoagulant therapy was 2.5 to 3.5 INR; the best target value was 3.0 INR. Conclusion. The risk of hemorrhage with
anticoagulant therapy is high in patients with ischemic stroke of arterial origin but is mainly confined to early use and
elderly patients.
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Patients with atrial fibrillation1 or myocardial
infarction2 4 benefit from treatment with coumarins;
however, treatment introduces a moderate annual
bleeding risk of 2% to 3%. A study of coumarins in
patients with atrial fibrillation and recent nondis-
abling cerebral ischemia showed a 65% reduction of
recurrent strokes with an accompanying annual
bleeding risk of less than 3% percent.5 These results
suggest that oral anticoagulation may prevent stroke
in a wider ränge of indications.
To investigate whether coumarins also could im-
prove the outcome for patients with stroke of noncar-
diac origin, the Stroke Prevention in Reversible
Ischemia Trial (SPIRIT) was designed. SPIRIT was
an open, multicenter clinical trial in which patients
with cerebral ischemia of presumed arterial origin
were randomized between low-dose aspirin (30 mg
daily) and full-dose anticoagulation (international
normalized ratio [INR], 3.0 to 4.5).6 The trial was
prematurely terminated after the first interim analy-
sis revealed an excessive rate of bleeding complica-
tions (7% per year) in patients randomized to oral
anticoagulation. Subsequent analyses revealed dif-
ferences between patients that might help to explain
the observed risks; high INR levels äs well äs the
presence of leukoaraiosis appeared to be related to
the bleeding risk in particular.6 7
We thought that more data were needed to judge
the effect of coumarins in patients with cerebral is-
chemia of noncardiac origin. Therefore, we decided to
evaluate the anticoagulant therapy of patients with
cerebral ischemia of arterial origin who were treated
routinely in the Leiden anticoagulation clinic. With
the use of our extensive database, we calculated inci-
dence rates of bleeding and thromboembolic events
and searched for factors that contributed to the oc-
currence of events.
Furthermore, we determined the optimal intensity
of oral anticoagulation, defined äs the INR level that
offers the best balance between prevention of throm-
boembolism and occurrence of bleeding complica-
tions. The position of this balance would teil us
whether lowering the bleeding risk by a downshift of
the target level, äs suggested by the SPIRIT investi-
gators, is outweighed by increased thromboembolic
events.
Methods. Oral anticoagulation clmics. In the Nether-
lands, regional anticoagulation clinics monitor all patients
on oral anticoagulant.8 Patients visit the anticoagulation
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clinic every l to 6 weeks (average interval, 3 weeks) or are
visited at home. During each visit, a nurse takes a short
medical history with special attention to bleeding and throm-
boembolic events, changes in medication, intercurrent dis-
eases, and hospital admissions. An antecubital blood sample
is taken and prothrombin time is measured. Prothrombin
times are expressed in INR, the international Standard for
assessing intensity of oral anticoagulation.9 Until autumn
1996, the target ränge for patients receiving anticoagulant
therapy because of a prior stroke was 3.0 to 4.5 INR. After-
ward, it was lowered and set at 2.5 to 3.5 INR.
Patients. Because we sought to study anticoagulated
patients with cerebral ischemia of noncardiac origin, we
searched among the population of the Leiden anticoagula-
tion clinic for patients who met this criterion. We included
patients without cardiac embolic sources (i.e., without
atrial fibrillation or cardiac thrombus) who were treated
for cerebral ischemia between January l, 1994, and Janu-
ary, l 1998. Because antiplatelet agents, rather than cou-
marins, are the Standard treatment for ischemic stroke in
the Netherlands, the selected patients may not be repre-
sentative of the general population of Dutch stroke
survivors.
To determine whether registration of the anticoagula-
tion clinic was reliable in distinguishing between patients
with and without cardiac embolic sources, we took a ran-
dom sample of 20 patients and evaluated their füll medical
charts. In 16 patients, no cardiac embolic source could be
demonstrated, 3 had atrial fibrillation, and l had a cardiac
thrombus on ultrasound.
Data collectwn. We included the following Information
from the computerized records: date of the index ischemic
cerebral event and start of anticoagulant treatment, dura-
tion of treatment, date of birth, sex, dates and results of all
prothrombin times, hospital admissions, and death. These
data are at all times routinely collected by the anticoagu-
lation clinic.
To register events on follow-up, we additionally col-
lected discharge letters for all hospital admissions during
the period of the study along with relevant results of labo-
ratory tests, radiographs, CT scans, and autopsy reports.
When patients died outside the hospital, we contacted
their general practitioners about the cause of death.
Outcome events. Primary outcome events were major
hemorrhages (intracranial, spinal, and extracranial) and
arterial thromboembolic events (ischemic stroke, myocar-
dial infarction, and peripheral embolism). Death (vascular
and nonvascular) was considered a secondary outcome
event.
Intracranial and spinal hemorrhage was defined äs a
neurologic deficit of sudden or subacute onset, confirmed
by surgery, autopsy, or CT scan. Major extracranial hem-
orrhage was defined äs acute blood loss, outward or in-
ward, leading to death or to hospital admission for
observation or treatment. Admission for diagnostic pur-
poses only was not considered major extracranial hemor-
rhage, nor was a bleeding event that occurred while the
patient was admitted. The diagnosis of ischemic stroke
required a neurologic deficit of acute onset, proven by au-
topsy or CT scan. Myocardial infarction was defined by two
of the following: history of ehest discomfort, typical rise of
specific cardiac enzymes, or the development of new Q
waves on EKG. Peripheral embolism was defined äs sud-
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den peripheral ischemia, proven by duplex scanning, an-
giography, surgery, or autopsy. Death from vascular
diseases included sudden death (reliable observation of the
time between onset of Symptoms and death or the patient
being found dead) or death from myocardial infarction,
congestive heart failure, peripheral embolism, stroke, pul-
monary embolism, any bleed, or other vascular causes.
An expert panel, composed of a cardiologist, neurologist,
internist, and clinical epidemiologist, classified all events
according to these definitions. The panel members were at
all times blinded for the intensity of anticoagulation at the
time of the event.
Optimal intensity of anticoagulation. The optimal in-
tensity of anticoagulant therapy was defined äs the INR
ränge with the lowest incidence of untoward events.
Intensity-specific incidence rates were calculated äs the
ratio of the number of events that took place at a certain
INR level and the number of patient-years that this inten-
sity level had been achieved by the total patient popula-
tion. INR-specific patient-years were computed using a
method that converts patient-time into INR time by as-
suming a linear relationship between consecutive INR
measurements.10 All days with the same achieved intensity
level are summed and grouped in intervals of 0.5 INR. The
INR at the time of an outcome event was obtained from the
hospital records. If the INR was not measured on hospital
admission or if the test result could not be retrieved, we
used the last INR measurement at the anticoagulation
clinic within 8 days before the event. If no suitable INR
was available, the event was disregarded for the calcula-
tion of incidence rates.
Data analysis. Incidence rates and their 95% CI were
derived by Standard calculations, based on the assumption
of a Poisson distribution of the number of events. A Cox
proportional hazards model was used to compare the inci-
dence of outcome events between groups. Differences be-
tween groups were expressed äs a hazard ratio (HR),
which is synonym to the relative risk.
The mortality data of our study and the SPIRIT trial
were standardized by age to allow comparison between the
studies. Standardization was performed by 5-year age cat-
egories, with the pooled age distribution äs weights.
Results. Patients. During the follow-up period, 381 pa-
tients were anticoagulated because of prior cerebral ische-
mia. Five patients had participated in the SPIRIT study
and were therefore excluded. Another 20 patients were
excluded because they were known to have atrial
fibrillation.
At the start of the study period, January l, 1994, 132
patients were treated for cerebral ischemia that had oc-
curred before that date, whereas 224 patients had an ische-
mic cerebral event between January l, 1994, and January
l, 1998, and were subsequently treated with coumarins. In
180 patients, treatment was discontinued: 63 patients
died, 11 stopped after a bleeding event, 28 moved out of
the region to another anticoagulation clinic, 48 switched to
aspirin, and 30 patients discontinued treatment for other
reasons.
The total observation time was 644 patient-years, the
mean observation per patient was 1.8 years. The mean age
of the patients was 69 years, ranging from 24 to 93. Forty-
five percent were women. During the 4 years of follow-up,





























































' The number of patient-years is the maximum follow-up period,
based on the secondary outcome event "death of all causes."
Because follow-up ended when the endpoint of interest oc-
curred, the number of patient-years differs slightly between
endpoints. The incidence rate is expressed per 100 patient-
years.
217 hospital admissions in 139 patients were reported.
Sufficient clinical Information was available in 98% of the
admissions.
Anticoagulant control. During the follow-up period,
10,628 INR measurements were routinely performed at
the anticoagulation clinic. The average period between two
measurements was 3 weeks. In the initial 6 months of
treatment, 55% of the follow-up time was spent within the
target ränge. Approximately 68% of the time was spent
within this intensity ränge overall. Thirty patient-years
were not allocated to an INR interval because the duration
between two measurements exceeded 8 weeks.10
Incidences of primary and secondary outcome events.
Table l presents an overview of all outcome events. Suffi-
cient clinical data were available to classify all strokes äs
either hemorrhagic or ischemic. Twenty-five patients had a
major bleeding event (3.9 per 100 patient-years; 95% CI,
2.5 to 5.7) of which nine were fatal (1.4 per 100 patient-
years; 95% CI; 0.6 to 2.5): seven patients had a fatal intra-
cranial hemorrhage and two patients died because of
massive gastrointestinal blood loss. Nonfatal bleeding
events were intracranial (3), gastrointestinal (7), urogeni-
tal (2), muscular (1), retroperitoneal (1), joint (1) and nose
INR
Figure 1. International normalized ratio (INR)-specific
incidence rates of all primary outcome events. The corre-
sponding numbers are presented in table 2. The dotted
lines represent the 95% CI.
bleeds (1). The incidence of fatal and nonfatal intracranial
hemorrhage combined was 1.6 per 100 patient-years (95% CI,
0.7 to 2.7).
Nineteen patients had thromboembolic events (3.0 per
100 patient-years; 95% CI, 1.8 to 4.6). Two ischemic
strokes and two myocardial infarctions were fatal, yielding
an incidence rate for fatal thromboembolism of 0.6 per 100
patient-years (95% CI, 0.2 to 1.4). Nonfatal thromboem-
bolic events were ischemic stroke (10) and myocardial in-
farction (5).
A total of 63 patients died during follow-up (9.8 per 100
patient-years; 95% CI, 7.5 to 12.4). The cause of death
could be retrieved for all but one patient. In 37 patients,
the cause of death was classified äs vascular (5.7 per 100
patient-years; 95% CI, 4.0 to 7.8). Thirteen patients died
because of primary outcome events. The causes of death
for the remaining 24 patients were cardiac, presumed myo-
cardial infarction (1), the sequel of a primary cardiac event
(2), or congestive heart failure (2); cerebral, acute onset of
neurologic deficit without hospital admission (5) or slow
deterioration after multiple infarctions (3); vascular, pul-
monary embolism (1) and aortic dissection (1); and sudden
death (9).
Optimal intensity of anticoagulation. We were able to
retrieve INR values at the time of the event for 41 of 44
patients who had primary outcome events. Thirty-six pro-
thrombin times were measured directly after the event,
whereas five INR values were obtained from the records of
the anticoagulation clinic and had been determined within
8 days before the event.
Figure l shows the incidence rates of all combined un-
toward events and their 95% CI per INR interval. The
lowest incidence (2.3 per 100 patient-years; 95% CI, 0.6 to
5.1) was found between 3.0 and 3.5 INR; the incidence
rates rose steeply below 2.0 and over 4.5 INR. The position
of the curve remained basically unaltered if the 24 patients
who died from vascular causes outside the hospital also
were taken into account.
Table 2 presents INR-specific incidence rates of all
major bleeding and thromboembolic events. The risk ratio
for hemorrhage was 1.8 per 0.5 INR unit increase (95% CI,
1.5 to 2.3).
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* Incidence per 100 patient-years.
INR = international normalized ratio.
Risk factor analyses. Age. To assess the effect of age
on the occurrence of outcome events in our study, we drew
Kaplan-Meier curves for all primary outcome events (fig-
ure 2A) and overall survival (figure 2B). Advanced age had
a considerable effect on the occurrence of primary outcome
events (HR for age >65 years, 1.7; 95% CI, 0.8 to 3.4) and
an even more profound effect on survival (HR, 2.4; 95% CI,
1.3 to 4.7).
Further analyses of the relationship between age and
primary outcome events revealed a different effect of age
on bleeding and on thromboembolism. Advanced age was a
significant risk factor for the occurrence of major bleeding
(HR, 3.7; 95% CI, 1.1 to 12.3) but did not increase the risk
of thromboembolism (HR, 0.7; 95% CI, 0.3 to 1.8).
Duration of treatment. In clinical trials such äs
SPIRIT, most patients randomized to oral anticoagulation
are new to coumarins therapy. In our study, however, a
number of patients had already been treated with couma-
rins for years before follow-up started and, therefore, we
could assess long-term effects. We divided into five catego-
ries the time interval between the cerebral ischemic event
that led to prescription of coumarin and the start of
follow-up in our study, with the shortest time interval (up
to 3 months) äs the reference category. The hazard ratio
for all primary outcome events was 0.94 (95% CI, 0.13 to
6.95) for patients who entered the study between 3 and 6
months after the index event. After the first 6 months, the
hazard ratios decreased to 0.28 in the second half-year
(95% CI, 0.04 to 2.07), to 0.20 after l to 3 years (95% CI,
0.03 to 1.48) and to 0.55 after more than 3 years (95% CI,
0.28 to 1.10), indicating that the risk of untoward events is
highest in the first 6 months after cerebral ischemia.
To further quantify these differences, we analyzed
Starters and long-term users separately (table 3). The 228
Starters (276 patient-years) were new to oral anticoagula-
tion or used coumarins for less than 6 months when
follow-up started, whereas the 128 long-term users (368
patient-years) had already been treated with oral antico-
agulants for more than 6 months after an episode of cere-
bral ischemia. Elderly patients (>65 years of age) were
equally represented in both groups (69.3% versus 71.9%).
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Twenty-nine primary outcome events were counted in the
Starters group. Nine patients had cerebral hemorrhages
(3.3 per 100 patient-years; 95% CI, 1.5 to 5.8), of which six
were fatal. The overall incidence of major bleeding events
was 6.2 per 100 patient-years (95% CI, 3.6 to 9.6). Starters
also had a high incidence of thromboembolic events. The
incidence rate of all combined thromboembolic endpoints
was 4.5 per 100 patient-years (95% CI, 2.3 to 7.4). Among
the long-term users, 15 primary outcome events occurred.
There was only one cerebral hemorrhage among the eight
bleeding events (2.2 per 100 patient-years; 95% CI, 0.9 to
4.0). The overall incidence of thromboembolic events was
less than half of that in the Starters group (1.9 per 100
patient-years; 95% CI, 0.8 to 3.7).
Therefore, starters had a 2.6-fold higher risk of unto-
ward events than did long-term users (95% CI, 2.5 to 2.6),
and that risk was composed both of a higher bleeding risk
(RR, 2.8; 95% CI, 2.6 to 3.0) and a higher thromboembolic
risk (RR, 2.4; 95% CI, 2.1 to 2.6).
Finally, we studied the occurrence of primary outcome
events in the first year of treatment after the episode of
cerebral ischemia by comparing the incidence rates in the
initial 6 months of anticoagulant therapy with the rates in
the second half-year. Results are presented in table 4. Dur-
ing the first 6 months of coumarin therapy, 10 hemor-
rhages (7 intracranial), four myocardial infarctions, and
four ischemic strokes occurred in 83 patient-years, yielding
incidence rates of 12.0 per 100 patient-years (95% CI, 5.6
to 20.9) for major hemorrhage and of 9.7 per 100 patient-
years (95% CI, 4.1 to 17.8) for thromboembolism. In the
second half-year (62 patient-years) two extracranial hem-
orrhages (3.2 per 100 patient-years; 95% CI, 0.3 to 9.4) and
three arterial thromboses (4.9 per 100 patient-years; 95%
CI, 0.9 to 12.1) were registered.
These numbers yield a RR of 2.7 (95% CI, 2.4 to 3.1) in
detriment of the first 6-month period for all primary out-
come events and of 3.8 (95% CI, 1.9 to 7.6) for hemorrhage
only. The overall incidence rate of primary outcome events
in the first year of anticoagulant treatment was 8.3 per
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Figure 2. (A) Kaplan-Meier curve for all primary outcome
events according to age older than and younger than 65
years. (B) Kaplan-Meier curve for overall survival accord-
ing to age older than and younger than 65 years.
orrhage, 4.8 (95% CI, 1.9 to 9.2) for intracranial bleeding,
and 7.6 (95% CI, 3.7 to 12.9) for arterial thromboembolism.
Discussion. To study the effect of coumarins in
patients with cerebral ischemia of noncardiac origin,
we performed an observational study among patients
of a Dutch anticoagulation clinic. In these patients,
we found an overall bleeding incidence of 3.9 per 100
treatment-years (95% CI, 2.5 to 5.7), which is less
than the annual bleeding risk in a previous random-
ized trial (7.0; 95% CI, 5.4 to 9.3)6 but higher than
the bleeding incidences in studies of other indica-
tions (2% to 3%).1>3 Risk factor analyses revealed a
major effect of age (HR for age >65 years, 3.7), dura-
tion of anticoagulant treatment after cerebral ische-
mic event (RR in the first 6 months, 3.8), and of the
achieved intensity of oral anticoagulation (RR, 1.8
for each 0.5 INR unit increase) on the occurrence of
bleeding events.
Differences between the outcomes of our study
and the randomized trial (SPIRIT) may be because of
distinct patient characteristics such äs the age distri-
bution of participants: 71% of our patients were older
than 65 years (65 to 93; mean, 75) versus only 47%
in SPIRIT. Part of the high mortality rate in our
study can be explained by this difference. When
standardized according to age, the mortality rate in
our cohort declined from 9.8 to 8.2 per 100 patient-
years, whereas that of spirit increased from 4.5 to
5.0 per 100 patient-years. The remaining surplus of
secondary endpoints may be explained by a less fa-
vorable risk profile of the routinely treated patient
group compared with the patients in the randomized
trial.
We also found an association between age and risk
of hemorrhage, a relationship that has already been
described extensively in the literature.11·12 The in-
creasing bürden of comorbidity in the elderly may
explain this finding.12·13
The incidence of thromboembolism in Starters was
more than twice äs high äs in long-term users of oral
anticoagulant therapy. There are several possible ex-
planations for the high incidence rate among Start-
ers. First, the intensity of oral anticoagulation is
often unstable in the starting phase of anticoagulant
treatment. In our study, 55% of the observation time
during the first 6 months of treatment was spent in
the target ränge compared with 70% thereafter. Be-
cause the risk of thromboembolism rises steeply if
the achieved intensity level drops below 2.0 INR,
more thromboembolic events are expected in the first
months of therapy. Second, the risk of a recurrent
event may be high during the first few months after
cerebral ischemia. Even if anticoagulation has been
adequate, the thromboembolic risk might have ex-
ceeded its preventive capacities.
We also found a considerable difference in bleed-
ing rates between Starters and long-term users.
Long-term users, who received oral anticoagulation
for at least 6 months before our study, had bleeding
rates comparable with those in other studies; the
annual rates of 0.5% for fatal and 2.2% for major
hemorrhages are very similar to the results of a pre-
vious study on the bleeding risk for all patients of
the Leiden anticoagulation clinic.14 Starters, how-
ever, had a nearly three times greater bleeding inci-
dence (6.2 per 100 patient-years) than long-term
users, mainly because of an excessive number of ce-
rebral hemorrhages. The excess of cerebral bleeding
events in Starters clustered exclusively in the initial
6 months of coumarin therapy. When we considered
the entire first year of treatment, the incidence of
hemorrhage was 8.3 per 100 patient-years (95% CI,
4.2 to 13.7), which corresponds very well with the
SPIRIT trial, in which a bleeding incidence of 7.0
(95% CI, 5.4 to 9.3) was found.
In general, the bleeding incidence among antico-
agulated patients tends to be higher during the first
December (l of 2) 2001 NEUROLOGY 57 1997



























































































""" The number of patient-years between parentheses is the maximum follow-up period, based on the secondary outcome event "death of
all causes." Because follow-up ended when the endpoint of interest occurred, the number of patient-years differs slightly between end-
points. The incidence rate is expressed per 100 patient-years.
months of treatment.11 The instability of anticoagu-
lation during the starting phase of oral anticoagu-
lant therapy and also the increased vulnerability of
patients with an existing (silent) bleeding site partly
explain this phenomenon. Because the excess num-
ber of bleeding events in patients with cerebral ische-
mia of noncardiac origin exclusively concerned
intracranial and not extracranial hemorrhage, it is
















































* The number of patient-years is the maximum follow-up period, based on the secondary outcome event "death of all causes." Because
follow-up ended when the endpoint of interest occurred, the number of patient-years differs slightly between endpoints. The incidence
rate is expressed per 100 patient-years.
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reasonable to look for intracranial abnormalities
that distinguish the patients at high risk from other
patients. Several attempts have been made to iden-
tify these patients.6·7 Leukoaraiosis—a white matter
abnormality on CT scan—is a potential risk factor.
Leukoaraiosis often results from structural changes
in small cerebral arteries and arterioles15 and might
lead to increased fragility of the vessel wall and sub-
sequent bleeding.16 However, different forms of leu-
koaraiosis exist and their precise role and meaning
are not yet fully understood. Arterial hypertension
was also identified äs a risk factor for bleeding,11'16
but opposite results have been published äs well.12·17
Further research will be necessary to identify pa-
tients with high bleeding risk to offer them a differ-
ent treatment.
Many studies have already proven the value of
determining optimal intensity of oral anticoagulation
by using the actual achieved intensity of oral
anticoagulation.17-19 The optimal intensity level of
oral anticoagulation in this cohort was between 3.0
and 3.5 INR. Preferably, most treatment time should
be spent in this ränge to minimize the occurrence of
untoward events, whereas intensity levels below 2.0
and above 4.5 INR should be avoided. To reach these
goals, a target level of 2.5 to 3.5 INR with a target
value of 3.0 INR may be the most appropriate. This
target level is considerably lower than intensities
used in the SPIRIT trial (3.0 to 4.5 INR) and comes
close to the applied intensities (2.0 to 3.0 INR) in an
ongoing trial on the secondary prevention of cerebral
ischemia in low-risk patients with cerebral ischemia
of presumed arterial origin.20
Because we performed an observational study,
cardiac sources of embolism might have been present
more often in our patients than in the anticoagulated
cohort of the randomized trial (SPIRIT). Indeed, 15%
of the pilot sample that we investigated extensively
had atrial fibrillation and were consequently mis-
classified by the anticoagulation clinic. One patient
was diagnosed with a thrombus in the heart, but this
was looked for neither äs inclusion nor äs exclusion
criterion in the SPIRIT trial.
The participation of patients with stroke of car-
diac origin in our study may have led to an underes-
timation of bleeding incidence in long-term users
because cardiac patients have a bleeding risk of only
less than 3%.5 It therefore is too soon to postulate
that oral anticoagulant therapy for patients with ce-
rebral ischemia of presumed arterial origin is safe
for long-term treatment and that the initial high
bleeding risk is the only problem to overcome. How-
ever, further study of the alarming outcomes of the
SPIRIT trial revealed subgroups with a very high
bleeding risk. Oral an'ticoagulant treatment for pa-
tients with cerebral ischemia of noncardiac origin is
still being debated.
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